GHIT 3.0: Investing in Japanese health technology through public-private partnerships to combat infectious diseases in LMICs

Since 2013, GHIT has invested $276M in 114 projects, using its signature private-public partnership model to advance global health R&D.

In GHIT 3.0, the next phase of its work, GHIT will (1) continue to pursue its core mandate of funding R&D programs to combat tuberculosis, malaria, and neglected tropical diseases by maximizing the efficiency of its portfolio and accelerating the progression of its most promising products through the critical milestones of regulatory approval and launch; and (2) invest in a carefully curated bank of “repurposable” technologies.

These are technologies that can be applied to both the endemic diseases that disproportionately affect LMICs and the as-yet-unknown pathogens that will cause future pandemics.

In less than a decade, the collaboration between GHIT and the Wellcome Trust has attracted talent, resources, and expertise to neglected communicable diseases in Japan and globally, with one novel product already CE-marked, one on the verge of approval, and many more in the pipeline.

If GHIT 3.0 is able to benefit from the combined knowledge, resources, and vision of GHIT and the Wellcome Trust, it has the potential to significantly impact the global health R&D ecosystem in the next 5-years, with dramatic implications for health in LMICs.